Clinical trial · Interventional
Aspirin on CTCs of Advanced Breast and Colorectal Cancer
NCT02602938CI-TRIAL-00019768ACABCunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether Aspirin could affect the number and subtype of circulating tumor cells of metastatic breast cancer and colorectal cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cells | — | UNRESOLVED | — |
| Epithelial-Mesenchymal Transition | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aspirin | Drug | Aspirin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- aspirin
- description
- * The included patients will be administered with aspirin (100mg) orally once a day in 28-day cycles. * The CTC was evaluated at baseline, and every 28 days for 2 months.
- interventionNames
- Drug: Aspirin
Primary outcomes (1)
- measure
- Intervention completed
- timeFrame
- 2 months
- description
- 2-months follow-up completed and the CTCs' assessment was evaluated three times by Canpatrol technology, the tumor burden was evaluated by MRI or CT.
Secondary outcomes (1)
- measure
- Disease progression
- timeFrame
- 2 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Adults age from 18-75 years old. * Patients were diagnosed for metastatic breast or colorectal cancer by pathology. * Patients who were not currently receiving intravenous chemotherapy , oral administrated with capecitabine was permitted. * Concurrent endocrine therapy ( for at least 2 months before enrollment), bisphosphonate therapy, and/or monoclonal targeted therapy were permitted. * PS score ≤ 3 * Anticipated survival time ≥ 3 months * CTCs≥5 / 7.5ml blood Exclusion Criteria: * Allergic to aspirin or other types of non-steroid * History of hemorrhage of digestive tract or other hemorrhagic disease * Plan to receive surgery within the time frame of the trial * Medication history of aspirin or other types of anti-platelets drug within one months before the trial * Women in pregnant or lactation period * Any psychological or objective problem may influence the compliance of the patients
References
Publications (4)
- BACKGROUNDKsiazkiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology. 2012;79(4):195-208. doi: 10.1159/000337106. Epub 2012 Apr 4. PMID 22488297
- BACKGROUNDRothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012 Apr 28;379(9826):1591-601. doi: 10.1016/S0140-6736(12)60209-8. Epub 2012 Mar 21. PMID 22440947
- BACKGROUNDMaity G, De A, Das A, Banerjee S, Sarkar S, Banerjee SK. Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. Lab Invest. 2015 Jul;95(7):702-17. doi: 10.1038/labinvest.2015.49. Epub 2015 Apr 13. PMID 25867761
- DERIVEDYang L, Lv Z, Xia W, Zhang W, Xin Y, Yuan H, Chen Y, Hu X, Lv Y, Xu Q, Weng X, Ni C. The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. Clin Transl Oncol. 2018 Jul;20(7):912-921. doi: 10.1007/s12094-017-1806-z. Epub 2017 Dec 14. PMID 29243075